1. Pink Sheet
  2. >>Vaccines

EMA Assessing 'Slightly' Raised Heart Attack Risk With Two COVID-19 Vaccines

Moderna's Spikevax Linked To Flare-Up Of Capillary Leak Syndrome

 
• By Ian Schofield

The EU’s latest safety report on coronavirus vaccines looks at the risk of myocardial infarction, pulmonary embolism, thrombosis and capillary leak syndrome following vaccination.

The concept of a coronavirus vaccine. syringe and covid-19 virus on a white background
The safety of COVID-19 vaccines is kept under constant surveillance • Source: Alamy

The European Medicines Agency’s pharmacovigilance risk assessment committee (PRAC) has begun evaluating reports of myocardial infarction following the administration of two coronavirus vaccines, COVID-19 Vaccine Janssen and AstraZeneca PLC/Oxford University’s Vaxzevria. Reports of pulmonary embolism and thromboses with Vaxzevria are also being investigated.

The EMA said PRAC was aware of the results of an epidemiological study based on French national databases and posted...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Japan To Cut Leqembi Price By 15% Following Cost Effectiveness Review

 
• By Lisa Takagi

While the government announces eight to 15% cuts to the four products, industry groups urges for its operational improvement without expansion.

Precigen’s Papzimeous Approval Allows US FDA CBER Director To Emphasize Flexibility

 
• By Bridget Silverman

Returning FDA biologics center director Vinay Prasad used the Papzimeous approval announcement to reinforce his flexibility on rare disease therapies after several complete response letters and his brief departure from the agency.

Generic Drug Industry Seeks More US FDA Communication Reforms In GDUFA Renewal

 
• By Sue Sutter

Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.